Combination of HDAC and topoisomerase inhibitors in small cell lung cancer

著者: Gray, Jhanelle, Cubitt, Christopher L., Zhang, Shumin, Chiappori, Alberto
出版事項 2012

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

著者: Turner, Joel G., Dawson, Jana, Cubitt, Christopher L., Baz, Rachid, Sullivan, Daniel M.
出版事項 2014

Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines

著者: Welch, Darcy, Kahen, Elliot, Fridley, Brooke, Brohl, Andrew S., Cubitt, Christopher L., Reed, Damon R.
出版年 PLoS One (2019)

MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines

著者: Almhanna, Khaldoun, Cubitt, Christopher L, Zhang, Shumin, Kazim, Sabiha, Husain, Kazim, Sullivan, Dan, Sebti, Said, Malafa, Mokenge
出版事項 2013

Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma

著者: Kahen, Elliot, Yu, Diana, Harrison, Douglas J., Clark, Justine, Hingorani, Pooja, Cubitt, Christopher L., Reed, Damon R.
出版年 Cancer Chemother Pharmacol (2016)

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

著者: Turner, Joel G., Dawson, Jana, Emmons, Michael F., Cubitt, Christopher L., Kauffman, Michael, Shacham, Sharon, Hazlehurst, Lori A., Sullivan, Daniel M.
出版事項 2013

Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma

著者: Yu, Diana, Kahen, Elliot, Cubitt, Christopher L., McGuire, Jeremy, Kreahling, Jenny, Lee, Jae, Altiok, Soner, Lynch, Conor C., Sullivan, Daniel M., Reed, Damon R.
出版年 Sci Rep (2015)

Inhibition of ER stress–associated IRE-1/XBP-1 pathway reduces leukemic cell survival

著者: Tang, Chih-Hang Anthony, Ranatunga, Sujeewa, Kriss, Crystina L., Cubitt, Christopher L., Tao, Jianguo, Pinilla-Ibarz, Javier A., Del Valle, Juan R., Hu, Chih-Chi Andrew
出版事項 2014

Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma

著者: Turner, Joel G., Cui, Yan, Bauer, Alexis A., Dawson, Jana L., Gomez, Juan A., Kim, Jongphil, Cubitt, Christopher L., Nishihori, Taiga, Dalton, William S., Sullivan, Daniel M.
出版年 Cancer Res (2020)

Rapid Screening of Novel Agents for Combination Therapy in Sarcomas

著者: Cubitt, Christopher L., Menth, Jiliana, Dawson, Jana, Martinez, Gary V., Foroutan, Parastou, Morse, David L., Bui, Marilyn M., Letson, G. Douglas, Sullivan, Daniel M., Reed, Damon R.
出版事項 2013

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors conta...

著者: Garrett, Christopher R., Coppola, Domenico, Wenham, Robert M., Cubitt, Christopher L., Neuger, Anthony M., Frost, Timothy J., Lush, Richard M., Sullivan, Daniel M., Cheng, Jin Q., Sebti, Saïd M.
出版年 Invest New Drugs (2010)

Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining T(reg) and antitumor CTL function

著者: Betts, Brian C., Veerapathran, Anandharaman, Pidala, Joseph, Yang, Hua, Horna, Pedro, Walton, Kelly, Cubitt, Christopher L., Gunawan, Steven, Lawrence, Harshani R., Lawrence, Nicholas J., Sebti, Said M., Anasetti, Claudio
出版年 Sci Transl Med (2017)

Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors

著者: Kahen, Elliot John, Brohl, Andrew, Yu, Diana, Welch, Darcy, Cubitt, Christopher L., Lee, Jae K., Chen, Yunyun, Yoder, Sean J., Teer, Jamie K., Zhang, Yonghong O., Wallace, Margaret R., Reed, Damon R.
出版年 Oncotarget (2018)

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

著者: Sweet, Kendra, Komrokji, Rami, Padron, Eric, Cubitt, Christopher L., Turner, Joel G., Zhou, Junmin, List, Alan F., Sallman, David A., Dawson, Jana L., Sullivan, Daniel M., Chavez, Julio, Shah, Bijal D., Lancet, Jeffrey E.
出版年 Clin Cancer Res (2019)

Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases

著者: Schonbrunn, Ernst, Betzi, Stephane, Alam, Riazul, Martin, Mathew P., Becker, Andreas, Han, Huijong, Francis, Rawle, Chakrasali, Ramappa, Jakkaraj, Sudhakar, Kazi, Aslamuzzaman, Sebti, Said M., Cubitt, Christopher L., Gebhard, Anthony W., Hazlehurst, Lori A., Tash, Joseph S., Georg, Gunda I.
出版事項 2013

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth

著者: MARCHION, DOUGLAS C., BICAKU, ELONA, XIONG, YIN, ZGHEIB, NADIM BOU, SAWAH, ENTIDHAR AL, STICKLES, XIAOMANG BA, JUDSON, PATRICIA L., LOPEZ, ALEX S., CUBITT, CHRISTOPHER L., GONZALEZ-BOSQUET, JESUS, WENHAM, ROBERT M., APTE, SACHIN M., BERGLUND, ANDERS, LANCASTER, JOHNATHAN M.
出版年 Oncol Rep (2013)

The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer

著者: ZGHEIB, NADIM BOU, XIONG, YIN, MARCHION, DOUGLAS C., BICAKU, ELONA, CHON, HYE SOOK, STICKLES, XIAOMANG BA, AL SAWAH, ENTIDHAR, JUDSON, PATRICIA L., HAKAM, ARDESHIR, GONZALEZ-BOSQUET, JESUS, WENHAM, ROBERT M., APTE, SACHIN M., CUBITT, CHRISTOPHER L., CHEN, DUNG TSA, LANCASTER, JOHNATHAN M.
出版事項 2012

Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival

著者: BUSH, STEPHEN H., TOLLIN, SHARON, MARCHION, DOUGLAS C., XIONG, YIN, ABBASI, FOROUGH, RAMIREZ, INGRID J., ZGHEIB, NADIM BOU, BOAC, BERNADETTE, JUDSON, PATRICIA L., CHON, HYE SOOK, WENHAM, ROBERT M., APTE, SACHIN M., CUBITT, CHRISTOPHER L., BERGLUND, ANDERS E., HAVRILESKY, LAURA J., LANCASTER, JOHNATHAN M.
出版年 Mol Clin Oncol (2016)